



Genetic and Epigenetic Regulation in Cardiovascular Diseases: Omics-Based Approaches

Guest Editor:

Dr. Xiaoguang Sun

College of Medicine, University of
Arizona, Tucson, AZ, USA

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editor

Dear Colleagues,

This Special Issue focuses on the use of omics-based approaches to investigate the genetic and epigenetic regulation of cardiovascular diseases. The articles in this Special Issue cover a range of topics, including the use of transcriptomics and epigenomics to study heart failure, the identification of genetic variants associated with coronary artery disease, and analysis of DNA methylation patterns in atherosclerosis.

Overall, the Special Issue highlights the importance of understanding the genetic and epigenetic mechanisms underlying cardiovascular diseases, as this knowledge can inform the development of new diagnostic and therapeutic approaches. The use of omics-based approaches, which allow for the analysis of large amounts of data at the molecular level, is a key tool in this effort.

Dr. Xiaoguang Sun

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)